Skip to content

X Linked Agammaglobulinemia C0221026

Published: July 22, 2026Updated: August 20, 2026

X-linked agammaglobulinemia is an inherited immune deficiency where the body lacks sufficient infection-fighting antibodies, primarily affecting males. Lifelong immunoglobulin therapy and antibiotics help prevent serious infections.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Severe pneumonia

!

Septic arthritis

Generalized symptoms

(immunologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Recurrent bacterial infections

(immunologic)

Otitis media

(immunologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Immunoglobulin replacement therapy

Regular intravenous or subcutaneous immunoglobulin infusions to replace deficient antibodies and provide immune protection against bacterial infections. Dosing is individualized based on body weight and infection history.

medication
3

Prophylactic antibiotics

Long-term antibiotic prophylaxis, typically with trimethoprim-sulfamethoxazole, to prevent bacterial respiratory infections. May be adjusted based on culture results and infection frequency.

medication

Additional treatment options

Infection surveillance program

Regular clinical monitoring including pulmonary function tests and imaging to detect early signs of chronic lung disease or bronchiectasis. Prompt evaluation of any fever episodes.

monitoring

Infection prevention practices

Education on hand hygiene, respiratory precautions, and avoidance of crowds during peak respiratory virus seasons. Vaccination of household contacts with inactivated vaccines.

lifestyle

Pulmonary hygiene techniques

Chest physiotherapy and airway clearance techniques to maintain lung health and prevent mucus accumulation. Regular use of flutter valves or similar devices.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is X Linked Agammaglobulinemia C0221026?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Conley ME, Smith C, Gaspar HB, et al. International Consensus (ICON) statement on the management of X-linked agammaglobulinemia. J Clin Immunol. 2020;40(4):556-568.

guideline2020
2

Wasserman RL, Sorensen RU, Goodman S, et al. Subcutaneous immunoglobulin replacement therapy in X-linked agammaglobulinemia: a multicenter study. J Allergy Clin Immunol Pract. 2022;10(5):1289-1297.

clinical_trial2022
3

Hernandez-Trujillo VP, Leiva LE, Rao M, Orange JS. Update on X-linked agammaglobulinemia: clinical manifestations and therapeutic strategies. Immunol Allergy Clin North Am. 2021;41(3):421-440.

review2021
4

Liu Z, Al-Qazlan A, Gadhvi A, et al. Mortality and morbidity in X-linked agammaglobulinemia: a systematic review and meta-analysis. Clin Immunol. 2023;250:109-120.

meta_analysis2023

Medication Comparisons

Compare medications used to treat X Linked Agammaglobulinemia C0221026. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy